Lexicon Pharmaceuticals Stock Net Asset
| LXRX Stock | USD 0.77 0.04 4.94% |
Lexicon Pharmaceuticals fundamentals help investors to digest information that contributes to Lexicon Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Lexicon Stock. The fundamental analysis module provides a way to measure Lexicon Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lexicon Pharmaceuticals stock.
Lexicon | Net Asset |
Lexicon Pharmaceuticals Company Net Asset Analysis
Lexicon Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Lexicon Pharmaceuticals Net Asset | 229.43 M |
Most of Lexicon Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lexicon Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lexicon Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Lexicon Pharmaceuticals is extremely important. It helps to project a fair market value of Lexicon Stock properly, considering its historical fundamentals such as Net Asset. Since Lexicon Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lexicon Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lexicon Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Lexicon Total Assets
Total Assets |
|
Based on the recorded statements, Lexicon Pharmaceuticals has a Net Asset of 229.43 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Lexicon Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lexicon Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lexicon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Lexicon Pharmaceuticals by comparing valuation metrics of similar companies.Lexicon Pharmaceuticals is currently under evaluation in net asset category among its peers.
Lexicon Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Lexicon Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lexicon Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lexicon Pharmaceuticals' value.| Shares | Ameriprise Financial Inc | 2024-06-30 | 2.1 M | Opaleye Management Inc | 2024-06-30 | 1.9 M | Pinnacle Associates Inc | 2024-09-30 | 1.7 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.4 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.2 M | Northern Trust Corp | 2024-09-30 | 1.1 M | Braidwell Lp | 2024-09-30 | 801.6 K | Wellington Management Company Llp | 2024-06-30 | 738.6 K | Hennion & Walsh Asset Management Inc | 2024-09-30 | 731.1 K | Artal Group S A | 2024-06-30 | 175.1 M | Fmr Inc | 2024-09-30 | 49.9 M |
Lexicon Fundamentals
| Return On Equity | -1.36 | ||||
| Return On Asset | -0.44 | ||||
| Operating Margin | (36.40) % | ||||
| Current Valuation | 134.7 M | ||||
| Shares Outstanding | 361.49 M | ||||
| Shares Owned By Insiders | 1.15 % | ||||
| Shares Owned By Institutions | 82.00 % | ||||
| Number Of Shares Shorted | 28.65 M | ||||
| Price To Earning | 21.02 X | ||||
| Price To Book | 1.64 X | ||||
| Price To Sales | 53.35 X | ||||
| Revenue | 1.2 M | ||||
| Gross Profit | (52.68 M) | ||||
| EBITDA | (163.46 M) | ||||
| Net Income | (177.12 M) | ||||
| Cash And Equivalents | 61.97 M | ||||
| Cash Per Share | 0.34 X | ||||
| Total Debt | 106.06 M | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 3.85 X | ||||
| Book Value Per Share | 0.49 X | ||||
| Cash Flow From Operations | (161.9 M) | ||||
| Short Ratio | 10.26 X | ||||
| Earnings Per Share | (0.74) X | ||||
| Price To Earnings To Growth | (0.14) X | ||||
| Target Price | 5.08 | ||||
| Number Of Employees | 285 | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 278.96 M | ||||
| Total Asset | 229.43 M | ||||
| Retained Earnings | (1.77 B) | ||||
| Working Capital | 145 M | ||||
| Current Asset | 171.5 M | ||||
| Current Liabilities | 31.77 M | ||||
| Net Asset | 229.43 M |
About Lexicon Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lexicon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexicon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexicon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lexicon Stock Analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.